Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($2.32), $1.01 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $33.4 million versus the consensus estimate of $33.12 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2026 revenue of $130-150 million, versus the consensus of $133.7 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.